Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 15, pp. 1379-1389
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
Motoharu Shibusawa, Tetsuya Tanimoto
New England Journal of Medicine (2025) Vol. 392, Iss. 1, pp. 101-102
Closed Access | Times Cited: 1
Gekommen, um zu bleiben? Nivolumab in der Erstlinientherapie des Hodgkin-Lymphoms im fortgeschrittenen Stadium – eine strahlentherapeutische Nachlese der SWOG-S1826-Studie
Michael Oertel, Hans Theodor Eich
Strahlentherapie und Onkologie (2025)
Open Access
Mortality in survivors of adolescent and young adult cancer: progress and opportunities
Michael Roth, Amy M. Berkman
The Lancet Public Health (2025) Vol. 10, Iss. 1, pp. e8-e9
Open Access
Should adolescents and young adults with Hodgkin lymphoma be treated as children or adults?
Lucille Lew‐Derivry, Florian Chevillon, Pauline Brice, et al.
British Journal of Haematology (2025)
Open Access
PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study
Jia Jin, Dandan Meng, Yu Wen, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-10
Closed Access
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD
Chiara Rusconi, Angelica Barone, Andrea Visentin, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-9
Closed Access
Impact of Comorbidities on Prognosis and Treatment Outcomes in Elderly Patients with Hodgkin Lymphoma
Dávid Tóthfalusi, Boglárka Dobó, Fanni Borics, et al.
Clinics and Practice (2025) Vol. 15, Iss. 1, pp. 15-15
Open Access
Game of Thrones: The New King in Advanced-Stage Hodgkin Lymphoma
Tycel Phillips
The Hematologist (2025) Vol. 22, Iss. 1
Open Access
Combined targeted modality in cHL: a risky bet?
Paul J. Bröckelmann, Bastian von Tresckow
Blood (2025) Vol. 145, Iss. 3, pp. 249-251
Closed Access
Computational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
Antonio Santisteban‐Espejo, C. de la Fuente, Alipio Mangas, et al.
Journal of Clinical Pathology (2025), pp. jcp-209848
Closed Access
How to Design Next-generation of Antibody-Drug Conjugates for Cancer Treatment: Lessons from Unsuccessful Clinical Trials
Aiwen Jian, Zhao Guo, Jiawei Zhou, et al.
Cancer Letters (2025), pp. 217535-217535
Closed Access
Reply to the Letter to the Editor ‘Comments on the study of correlation between progression-free and overall survival in patients with Hodgkin lymphoma’ by Zeng et al.
Paul J. Bröckelmann, Bastian von Tresckow
Annals of Oncology (2025)
Closed Access
Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
Shiliang Ge, Kylie Lepic, R. Bhindi, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 118-118
Open Access
The mutational landscape and its longitudinal dynamics in relapsed and refractory classic Hodgkin lymphoma
Hanno M. Witte, Axel Künstner, Thomas F. Hahn, et al.
Annals of Hematology (2025)
Open Access
The Impact of Radiotherapy and Attenuated Chemotherapy Regimens in Older Patients with Classic Hodgkin Lymphoma: A Real-Life Study from the ReLLi Network
Maria Christina Cox, Matteo Caridi, Alexandro Patirelis, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 765-765
Open Access
Hodgkin lymphoma: great progress with room for improvement
Paul J. Bröckelmann
Nature Reviews Clinical Oncology (2025)
Closed Access
Twice the trouble, half the fun: twin study suggests future direction for young adults with Hodgkin lymphoma
Michael Daunov, Changchun Deng
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-3
Closed Access
Predicting risk in Hodgkin lymphoma for research and clinical practice
Ruohui Chen, Leo I. Gordon
Blood Advances (2025) Vol. 9, Iss. 6, pp. 1387-1389
Closed Access
Progression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma?
Naoto Yamauchi, Dai Maruyama
Annals of Oncology (2025) Vol. 36, Iss. 4, pp. 356-358
Closed Access
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
Timothy Voorhees, Eric McLaughlin, Pallawi Torka, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know
Xiaosu Zhao, Xiaotong Chen, Ying‐Jun Chang
Blood Science (2025) Vol. 7, Iss. 2, pp. e00229-e00229
Open Access
Hodgkin lymphoma
David Wrench
Medicine (2025)
Closed Access
The immunotherapy real estate of Hodgkin lymphoma
Christian Steidl
Blood (2025) Vol. 145, Iss. 14, pp. 1445-1447
Closed Access
Peripheral Neuropathy Incidence in Children, and Adolescents and Young Adults With Cancer and Medicaid Insurance in California
Renata Abrahão, Julianne J.P. Cooley, Justine M. Kahn, et al.
JCO Oncology Practice (2025)
Closed Access
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
Matthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
HemaSphere (2025) Vol. 9, Iss. 5
Open Access
Page 1 - Next Page

Scroll to top